This database contains 1433 studies, archived under the term: ""
Click here to filter this large number of results.
Influence of social support on cognitive change and mortality in old age: results from the prospective multicentre cohort study AgeCoDe
Eisele, Marion,
Zimmermann, Thomas,
Köhler, Mirjam,
Wiese, Birgitt,
Heser, Kathrin,
Tebarth, Franziska,
Weeg, Dagmar,
Olbrich, Julia,
Pentzek, Michael,
Fuchs, Angela,
Weyerer, Siegfried,
Werle, Jochen,
Leicht, Hanna,
König, Hans-Helmut,
Luppa, Melanie,
Riedel-Heller, Steffi,
Maier, Wolfgang,
Scherer, Martin
Background: Social support has been suggested to positively influence cognition and mortality in old age. However, this suggestion has been questioned due to inconsistent operationalisations of social support among studies and the small number of longitudinal studies available. This study aims to investigate the influence of perceived social support, understood as the emotional component of […]
The NIH stroke scale can establish cognitive function after stroke
Background: Cognitive impairment is an important but underrecognised consequence of stroke. We investigated whether a subset of items from the NIH Stroke Scale (NIHSS) could yield valid information on cognitive status in a group of stroke patients.; Methods: 149 stroke patients from the Göteborg 70+ Stroke Study were investigated after 18 months. We extracted 4 […]
Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial
Cooper, Sally-Ann,
Caslake, Muriel,
Evans, Jonathan,
Hassiotis, Angela,
Jahoda, Andrew,
McConnachie, Alex,
Morrison, Jill,
Ring, Howard,
Starr, John,
Stiles, Ciara,
Sullivan, Frank
Background: Early-onset dementia is common in Down syndrome adults, who have trisomy 21. The amyloid precursor protein gene is on chromosome 21, and so is over-expressed in Down syndrome, leading to amyloid β (Aβ) over-production, a major upstream pathway leading to Alzheimer disease (AD). Statins (microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), have pleiotropic effects including […]
The benefits of implementing a computerized intervention-management-system (IMS) on delivering integrated dementia care in the primary care setting
Eichler, Tilly,
Thyrian, Jochen René,
Fredrich, Daniel,
Kohler, Leonore,
Wucherer, Diana,
Michalowsky, Bernhard,
Dreier, Adina,
Hoffmann, Wolfgang
Background: A computerized Intervention-Management-System (IMS) has been developed and implemented to facilitate dementia care management. IMS is a rule-based expert decision support system that matches individual patient characteristics to a computerized knowledge base. One of the most important functionalities of IMS is to support the compilation of the individual intervention plan by systematically identifying unmet […]
Being overweight in midlife is associated with lower cognitive ability and steeper cognitive decline in late life
Dahl, Anna,
Hassing, Linda B.,
Fransson, Eleonor,
Berg, Stig,
Gatz, Margaret,
Reynolds, Chandra A.,
Pedersen, Nancy L.
Background: Although an increasing body of evidence links being overweight in midlife with an increased risk for dementia in late life, no studies have examined the association between being overweight in midlife and cognitive ability in late life. Our aim was to examine the association between being overweight in midlife as measured by body mass […]
Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Emre, Murat,
Tsolaki, Magda,
Bonuccelli, Ubaldo,
Destée, Alain,
Tolosa, Eduardo,
Kutzelnigg, Alexandra,
Ceballos-Baumann, Andrés,
Zdravkovic, Slobodan,
Bladström, Anna,
Jones, Roy
Background: Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB).; Methods: Patients (≥50 years […]
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy
Ellis, Ronald J.,
Badiee, Jayraan,
Vaida, Florin,
Letendre, Scott,
Heaton, Robert K.,
Clifford, David,
Collier, Ann C.,
Gelman, Benjamin,
McArthur, Justin,
Morgello, Susan,
McCutchan, J. Allen,
Grant, Igor
Objective: Despite immune recovery in individuals on combination antiretroviral therapy (CART), the frequency of HIV-associated neurocognitive disorders (HANDs) remains high. Immune recovery is typically achieved after initiation of ART from the nadir, or the lowest historical CD4. The present study evaluated the probability of neuropsychological impairment (NPI) and HAND as a function of CD4 nadir […]
Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET)
Drye, Lea T.,
Scherer, Roberta W.,
Lanctôt, Krista L.,
Rosenberg, Paul B.,
Herrmann, Nathan,
Bachman, David,
Mintzer, Jacobo E.
Background: Research on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes.; Methods: In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer […]